Benefit from temozolomide is limited to patients whose tumours exhibit methylation of the MGMT promoter region [3], and the acceptability of withholding temozolomide from patients with MGMT unmethylated tumours in the context of clinical trials has been validated. The gene discussed is MGMT; the disease is neoplasm.